Karan Pattni1, Daniel Hungerford2, Sarah Adams3, Iain Buchan4, Christopher P Cheyne5, Marta García-Fiñana5, Ian Hall6,7, David M Hughes5, Christopher E Overton6, Xingna Zhang4, Kieran J Sharkey8. 1. Department of Mathematical Sciences, University of Liverpool, Liverpool, UK. 2. Centre for Global Vaccine Research, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK. 3. Graphnet Health, Milton Keynes, UK. 4. Institute of Population Health, University of Liverpool, Liverpool, UK. 5. Department of Health Data Science, University of Liverpool, Liverpool, UK. 6. Department of Mathematics and School of Health Sciences, University of Manchester, Manchester, UK. 7. Joint Universities Pandemic and Epidemiological Research, Manchester, UK. 8. Department of Mathematical Sciences, University of Liverpool, Liverpool, UK. kjs@liverpool.ac.uk.
Abstract
BACKGROUND: From January to May 2021 the alpha variant (B.1.1.7) of SARS-CoV-2 was the most commonly detected variant in the UK. Following this, the Delta variant (B.1.617.2) then became the predominant variant. The UK COVID-19 vaccination programme started on 8th December 2020. Prior to the Delta variant, most vaccine effectiveness studies focused on the alpha variant. We therefore aimed to estimate the effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines in preventing symptomatic and asymptomatic infection with respect to the Delta variant in a UK setting. METHODS: We used anonymised public health record data linked to infection data (PCR) using the Combined Intelligence for Population Health Action resource. We then constructed an SIR epidemic model to explain SARS-CoV-2 infection data across the Cheshire and Merseyside region of the UK. Vaccines were assumed to be effective after 21 days for 1 dose and 14 days for 2 doses. RESULTS: We determined that the effectiveness of the Oxford-AstraZeneca vaccine in reducing susceptibility to infection is 39% (95% credible interval [34, 43]) and 64% (95% credible interval [61, 67]) for a single dose and a double dose respectively. For the Pfizer-BioNTech vaccine, the effectiveness is 20% (95% credible interval [10, 28]) and 84% (95% credible interval [82, 86]) for a single-dose and a double dose respectively. CONCLUSION: Vaccine effectiveness for reducing susceptibility to SARS-CoV-2 infection shows noticeable improvement after receiving two doses of either vaccine. Findings also suggest that a full course of the Pfizer-BioNTech provides the optimal protection against infection with the Delta variant. This reinforces the need to complete the full course programme to maximise individual protection and reduce transmission.
BACKGROUND: From January to May 2021 the alpha variant (B.1.1.7) of SARS-CoV-2 was the most commonly detected variant in the UK. Following this, the Delta variant (B.1.617.2) then became the predominant variant. The UK COVID-19 vaccination programme started on 8th December 2020. Prior to the Delta variant, most vaccine effectiveness studies focused on the alpha variant. We therefore aimed to estimate the effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines in preventing symptomatic and asymptomatic infection with respect to the Delta variant in a UK setting. METHODS: We used anonymised public health record data linked to infection data (PCR) using the Combined Intelligence for Population Health Action resource. We then constructed an SIR epidemic model to explain SARS-CoV-2 infection data across the Cheshire and Merseyside region of the UK. Vaccines were assumed to be effective after 21 days for 1 dose and 14 days for 2 doses. RESULTS: We determined that the effectiveness of the Oxford-AstraZeneca vaccine in reducing susceptibility to infection is 39% (95% credible interval [34, 43]) and 64% (95% credible interval [61, 67]) for a single dose and a double dose respectively. For the Pfizer-BioNTech vaccine, the effectiveness is 20% (95% credible interval [10, 28]) and 84% (95% credible interval [82, 86]) for a single-dose and a double dose respectively. CONCLUSION: Vaccine effectiveness for reducing susceptibility to SARS-CoV-2 infection shows noticeable improvement after receiving two doses of either vaccine. Findings also suggest that a full course of the Pfizer-BioNTech provides the optimal protection against infection with the Delta variant. This reinforces the need to complete the full course programme to maximise individual protection and reduce transmission.
Authors: Andrea L Bertozzi; Elisa Franco; George Mohler; Martin B Short; Daniel Sledge Journal: Proc Natl Acad Sci U S A Date: 2020-07-02 Impact factor: 11.205
Authors: Koen B Pouwels; Emma Pritchard; Philippa C Matthews; Nicole Stoesser; David W Eyre; Karina-Doris Vihta; Thomas House; Jodie Hay; John I Bell; John N Newton; Jeremy Farrar; Derrick Crook; Duncan Cook; Emma Rourke; Ruth Studley; Tim E A Peto; Ian Diamond; A Sarah Walker Journal: Nat Med Date: 2021-10-14 Impact factor: 53.440
Authors: Andrew William Byrne; David McEvoy; Aine B Collins; Kevin Hunt; Miriam Casey; Ann Barber; Francis Butler; John Griffin; Elizabeth A Lane; Conor McAloon; Kirsty O'Brien; Patrick Wall; Kieran A Walsh; Simon J More Journal: BMJ Open Date: 2020-08-05 Impact factor: 2.692
Authors: Buddhisha Udugama; Pranav Kadhiresan; Hannah N Kozlowski; Ayden Malekjahani; Matthew Osborne; Vanessa Y C Li; Hongmin Chen; Samira Mubareka; Jonathan B Gubbay; Warren C W Chan Journal: ACS Nano Date: 2020-03-30 Impact factor: 15.881
Authors: Jamie Lopez Bernal; Nick Andrews; Charlotte Gower; Eileen Gallagher; Ruth Simmons; Simon Thelwall; Julia Stowe; Elise Tessier; Natalie Groves; Gavin Dabrera; Richard Myers; Colin N J Campbell; Gayatri Amirthalingam; Matt Edmunds; Maria Zambon; Kevin E Brown; Susan Hopkins; Meera Chand; Mary Ramsay Journal: N Engl J Med Date: 2021-07-21 Impact factor: 91.245
Authors: Dominique J Barbeau; Judith M Martin; Emily Carney; Emily Dougherty; Joshua D Doyle; Terence S Dermody; Alejandro Hoberman; John V Williams; Marian G Michaels; John F Alcorn; W Paul Duprex; Anita K McElroy Journal: NPJ Vaccines Date: 2022-07-06 Impact factor: 9.399